UCSF Prostate Cancer Trial: PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer
Xaluritamig is a promising first‑in‑class T‑cell engager for treating metastatic castration‑resistant prostate cancer, showing encouraging early clinical activity and a favorable safety profile.
PROMOTE is a tissue and blood collection protocol enrolling patients with metastatic prostate cancer and other genitourinary malignancies to identify predictive markers of response to systemic therapy using genomic and liquid biopsy analyses.
Identifying predictive markers may guide personalized therapy decisions and improve outcomes for patients with aggressive genitourinary cancers.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Apalutamide Treatment and Metastasis‑free Survival in Prostate Cancer
- The prostate cancer conundrum revisited: Treatment changes and prostate cancer mortality declines
- The contemporary management of prostate cancer
- Extracellular TROP2 Fragment Identified as a Potential Biomarker and Metastasis Driver
- Overall survival of prostate cancer patients treated with Lu‑177 PSMA 617 (Pluvicto®) in a multidisciplinary setting— a single center experience